Verastem, Inc.
Clinical trials sponsored by Verastem, Inc., explained in plain language.
-
New drug cocktail targets hard-to-treat lung cancer mutation
Disease control OngoingThis study tests a combination of two or three experimental drugs (avutometinib, sotorasib, and defactinib) in people with a specific type of advanced lung cancer called KRAS G12C non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the …
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated May 15, 2026 12:07 UTC
-
New hope for pancreatic cancer: drug combo trial underway
Disease control OngoingThis study tests whether adding two experimental drugs (avutometinib and defactinib) to standard chemotherapy can help people with advanced pancreatic cancer that has spread. About 40 adults with untreated metastatic pancreatic cancer will take part. The goal is to see if the com…
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for rare ovarian cancer: drug combo tested in japanese patients
Disease control OngoingThis study tests a combination of two drugs, avutometinib and defactinib, in 16 Japanese patients whose low-grade serous ovarian cancer has come back after prior treatment. The goal is to see if the drugs can shrink or control the tumors. Participants must have a specific KRAS ge…
Phase: PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC